The "Biotherapy" Oncology and Neurology Center started its research back in 1992 with development and clinical application of oncofetal protein-based cancer immunotherapy methods. Later on, the research field was expanded and involved lymphotropic chemotherapy and conjugate chemotherapy using nDNA-based medications. Together with these researches the controlled whole body hyperthermia was being investigated. As an outcome there appeared hyperthermia therapies which have no analogues in the world and this became a significant step in the cancerous tumor treatment. The specialists of the Center have by now well-studied and tested these methods, worked out lists of indications and contraindications, designed therapy courses and studied their compatibility and eventually these therapies became a daily routine of the clinical department of the Center. However, the specialists of the Center still continue studying the application of the whole body hyperthermia for treatment of cancerous tumors of different localizations.
The "Biotherapy" Center specialists develop new and apply well-tested methods of using biological response modifiers such as recombinant interferon-a, tumor necrosis factor, interleukin-2, and other as the means of immunotherapy and immunochemotherapy. Other innovative and promising therapies include such as gene therapies based on monoclonal antibodies to specific tumor receptors, and new generations of chemotherapeutic agents of highly selective performance and practically no serious side-effects.
The research programs of the Center include demyelinating process neuroimmunology against severe forms of neurological disorders, and effective methods of progressive multiple sclerosis treatment. New therapies are also being developed for the treatment of other diseases such as diabetes, cirrhosis, diseases of the locomotor apparatus, and parasitosis.